Vicinitas Therapeutics
Biotech · San Francisco, US
Biotech developing targeted protein stabilisers (DUBTACs) for cancer and genetic disease
Funding history
| Date | Round | Amount |
|---|
| Aug 2022 | Series A Vicinitas Therapeutics, a San Francisco protein-stabilisation biotech, raised $65M Series A co-led by a16z and Deerfield Management. | $65M |
Investors
Andreessen HorowitzDeerfield Management
Similar companies in Biotech
Explore funding flow on EquityFlow →